Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

Trial Profile

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Influenza A virus vaccine H5N2 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2015 Results published in the Vaccine.
    • 18 Aug 2015 Results published in the Vaccine.
    • 06 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top